Skip to main content
. Author manuscript; available in PMC: 2021 Mar 20.
Published in final edited form as: Ann Intern Med. 2020 Mar 24;172(8):523–532. doi: 10.7326/M19-2945

Appendix Figure 1.

Appendix Figure 1.

Mean hemoglobin levels over time in participants with anemia at baseline (<130 g/L in men or <120 g/L in women) who received canakinumab, 50, 150, or 300 mg every 3 months, compared with those who received placebo.

DF = degrees of freedom.